Nolvadex Pediatric Exclusivity Extension Would Block Generics Until 2003
Executive Summary
AstraZeneca expects to receive a pediatric exclusivity extension for the breast cancer agentNolvadex (tamoxifen) based on studies in McCune-Albright syndrome